218779-74-9

Basic information

• Product Name: ethyl 4-(2-tert-butoxy-2-oxoethylidene)cyclohexanecarboxylate
• Synonyms: ethyl 4-(2-tert-butoxy-2-oxoethylidene)cyclohexanecarboxylate
• CAS NO: 218779-74-9
• Molecular Formula: C₁₅H₂₄O₄
• Molecular Weight: 268.34866
• Mol File: 218779-74-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-(2-tert-butoxy-2-oxoethylidene)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-tert-butoxy-2-oxoethylidene)cyclohexanecarboxylate(218779-74-9)
• EPA Substance Registry System: ethyl 4-(2-tert-butoxy-2-oxoethylidene)cyclohexanecarboxylate(218779-74-9)

Safety Data

• Hazardous Substances Data: 218779-74-9(Hazardous Substances Data)

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 27784-76-5 tert-butyl diethylphosphonoacetate 

Downstream Products

• 279240-89-0 4-carboxy-1-cyclohexylideneacetic acid 1,1-dimethylethyl ester 
• 279240-92-5 2-(4-(ethoxycarbonyl)cyclohexylidene)acetic acid 
• 218779-77-2 2-(4-(ethoxycarbonyl)cyclohexyl)acetic acid 

Relevant articles and documents

ATX MODULATING AGENTS

Compounds of formula (I) can modulate the activity of autotaxin (ATX).

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.

NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

2-Cyclohexyl quinazoline NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, amin

2-cyclohexyl quinazoline NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, amin

2-CYCLOHEXYL IMIDAZOPYRIDINE NMDA/NR2B ANTAGONISTS

4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C 1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C 6alkyl or aminocarbonyl chain a

2-cyclohexyl imidazopyridine NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino,

2-cyclohexyl benzimidazole NMDA/NR2B antagonists

Novel 4-substituted cyclohexanes substituted in the 1-position with 2-benzimidazoles, 2-imidazopyridines, or 4-imidazoles either directly or through a C1-C4alkyl, cycloalkyl, hydroxyalkyl, alkoxy or aminoalkyl chain are effective as